Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2

Interventions

Fluorouracil 155Oxaliplatin 133Leucovorin 124Capecitabine 90Irinotecan 88Radiotherapy 63Bevacizumab 61Cetuximab 38Folfox protocol 25Panitumumab 21Neoadjuvant Therapy 21Surgical Procedures, Operative 19Chemotherapy, Adjuvant 15Radiation 13Floxuridine 13Erlotinib Hydrochloride 13Early Intervention, Educational 13IFL protocol 11Drug Therapy 11Proctectomy 10Magnetic Resonance Spectroscopy 10Counseling 10Surveys and Questionnaires 8Sorafenib 8Psychiatric Rehabilitation 8Gene Expression Profiling 8Radiotherapy, Intensity-Modulated 7Immunohistochemistry 7Gemcitabine 7Celecoxib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Rectal Neoplasms × 2C4 antibody × Clear all
NCT03365882 2026-02-10

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

SWOG Cancer Research Network

Phase 2 Completed
240 enrolled 14 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

NCT00551421 2015-03-31

Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
17 enrolled 7 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡